Mirati Therapeutics (MRTX) Misses Q4 EPS by 76c

Mirati Therapeutics (NASDAQ: MRTX) reported Q4 EPS of ($3.72), $0.76 worse than the analyst estimate of ($2.96). Revenue for the quarter came in at $299 thousand versus the consensus estimate of $1.41 million.

For earnings history and earnings-related data on Mirati Therapeutics (MRTX) click here.

You May Also Be Interested In

• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• Pony AI (PONY) Reports Revenue Above Estimates
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business